47 results about "Ovarian cancer cell line" patented technology

The invention relates to a tryptanthrin copper complex with antitumor activity and a synthetic method thereof; the tryptanthrin copper complex with antitumor activity has a structure as shown below; the tryptanthrin copper complex has significant inhibitory effect on ovarian cancer cell line Skov3, has potential medicinal value, is expected to serve as a metal antitumor drug and belongs to the technical field of medicine.

The invention relates to a group of micro RNA related to a BafilomycinA1 liver cancer and ovarian cancer inhibition cell line, belonging to the technical field of medical biology. The preparation method comprises the following steps: respectively acting BafilomycinA1 on a liver cancer cell line BEL-7402 and an ovarian cancer cell line HO-8910, and detecting the in-vitro growth inhibition, apoptosis promoting and invasion inhibition effects of BafilomycinA1 on two cells by performing soft agar cloning formation assay, electron microscopy observation, apoptosis related enzyme detection and in-vitro invasion assay; respectively acting 400nM BafilomycinA1 on the liver cancer cell line BEL-7402 and the ovarian cancer cell line HO-8910 for 48 hours, collecting dosing cells and control cells, extracting the RNA, analyzing the high-flux micro RNA between the drug group and the control group by using Affymetrix GeneChip Human Gene Array micro RNA array, and verifying the differences of the micro RNA by using qPCR, thereby obtaining co-sensitive micro RNA of the two cells. According to the group of micro RNA sensitive to the BafilomycinA1, on one hand, the micro RNA has the cancer inhibition effectiveness corresponding to the BafilomycinA1; on the other hand, the micro RNA has obvious change in two tumor cells, and a basis is provided for targets designed by taking the micro RNA as a potential broad spectrum anti-cancer drug.

The invention relates to a TOP medicament resistant cell line human ovarian cancer, with a accession number of CGMCC No 1217, which is selecting human ovarian cancer cell line as parental cell, putting the cell into RPMI1640 culture medium containing 15% calf serum, putting into incubator with 5% CO2 and 37 DEG C to culture; acquiring cells in logarithmic growth phase, counting after digesting with 0.25% pancreatin, inoculating 5*105/ml into culture bottle according to amount of 5ml in each bottle, when cells adheres to wall after 24 hours, reacting for 2 hours with a TOP final content of 2160ng/ml, discarding culture medium, washing by phosphate buffer for 3 times, replacing fresh culture medium, second impulsing after growing is resumed, and repeatedly operating, until it is impulsed with medicament for 13 times. The cell line is constructed for 10 months, medicament resistance of cell is 10.67 per cell, P<0.01 comparing with sensitive cell, has cross resistance to mitoxantrone, camptothecin, vincristine besides resistance to TOP.

According to the invention, human ovarian cancer cell line HO-8910 is adopted as an induction object; with a high-dose impact method, and with an in-vitro induction method with gradually increased VP16 concentration and intermittent action, the human ovarian cancer multidrug resistant cell line HO-8910/VP16 is established. The cell ling is preserved at China General Microbiological Culture Collection Center on December 24th, 2012, and has a preservation number of CGMCC NO.7052. The cell line provided by the invention has typical multidrug resistance. With the cell line, an experiment basis is provided for further researching resistance reversal approaches.

The invention discloses a genistein derivative and a preparation method and application thereof. The preparation method includes the process steps of (1) synthesis of 5-fluorouracil-1 acetic acid, wherein 5-fluorouracil reacts with chloroacetic acid in an aqueous alkali solution to generate the 5-fluorouracil-1-acetic acid; (2) preparation of the genistein derivative, wherein 5-fluorouracil-1-acetic acid and genistein are dissolved in an organic solvent, a catalyst is added for reaction, the product is filtered and the filter cake is dried to prepare a new genistein derivative. The derivativehas good solubility in organic solvents, also has a good inhibition rate on liver cancer cell HepG2 and ovarian cancer cell line SKOV-3, and is expected to develop a new drug with an anti-tumor effect.

The present invention discloses c-MYC-siRNA formulation as a potential therapeutic target for cisplatin-resistant ovarian cancer. It is disclosed targeting c-MYC with small interfering RNA (siRNA) in the cisplatin-resistant ovarian cancer cell line inducing a significant cell growth arrest and inhibition of cell proliferation. Apoptosis and arrest of cell cycle progression were also observed after c-MYC-siRNA-based silencing of c-MYC. Furthermore, delivering nanoliposomal c-MYC-siRNA, decreased tumor weight and number of tumor nodules compared with a liposomal-negative control siRNA.

The invention discloses a pulmonary-metastasis-derived high-metastasis human ovarian cancer cell line as well as establishment and an application thereof. The pulmonary-metastasis-derived high-metastasis human ovarian cancer cell line is named as high-metastasis human ovarian cancer cell line A2780-M which is preserved in CCTCC (China Center for Type Culture Collection) on Jan 22, 2017 with the preservation number being CCTCC NO: C201719. The high-metastasis human ovarian cancer cell line A2780-M is derived from human ovarian cancer cell line A2780, has more obvious proliferation activity and stronger metastasis function, invasion function and cell movement capacity than a maternal line, can serve as a reliable high-metastasis human ovarian cancer cell line and animal model for researching a molecular mechanism of ovarian cancer metastasis and can further provide a new target for clinical diagnosis and treatment, drug screening and prognosis.

Many cancer therapeutic agents elicit resistance that renders them ineffective and often produces cross resistance to other drugs. One of the most common mechanisms of resistance involves P-glycoprotein (Pgp) mediated drug efflux. Here we provide compositions and methods that restore the efficacy of a therapeutic agent reduced by resistance by conjugation of the same agent to an oligoarginine transporter comprising from about 5 to about 25 guanidino or amidino moieties. We specifically show that the widely used chemotherapeutic agent taxol, ineffective against taxol-resistant human ovarian cancer cell lines, can be incorporated into an octaarginine conjugate that is effective against the same taxol-resistant cell lines. Significantly, the ability of the taxol conjugates to overcome taxol resistance is observed both in cell culture and in animal models of ovarian cancer. The generality and mechanistic basis for this effect were also explored with other Pgp substrate. This approach shows generality for overcoming the multidrug resistance elicited by small molecule cancer chemotherapeutics and could improve the prognosis for many cancer patients and fundamentally alter search strategies for novel therapeutic agents effective against resistant disease.

The invention relates to the technical field of molecular biology and tumor marker medicine, in particular to circ-CRIM1 serving as an ovarian cancer diagnosis marker and application thereof. The biomarker for ovarian cancer diagnosis is circular RNA CRIM (circ-CRIM1), the nucleotide sequence of the circular RNA CRIM (circ-CRIM1) is shown as SEQ ID No.1, occurrence and development of ovarian cancer can be clearly represented, and the biomarker shows a specific high expression phenomenon in human clinical ovarian cancer tissue compared with corresponding normal ovarian tissue and also shows a specific high expression phenomenon in a human ovarian cancer cell line. The invention further discloses application of the ovarian cancer diagnosis biomarker circular circ-CRIM1 in preparation of ovarian cancer diagnosis products. The circ-CRIM1 serves as the ovarian cancer diagnosis marker, provides a molecular target for ovarian cancer treatment and can be applied to preparation of anti-tumor drugs.

The invention discloses a N-heterocyclic methyl tetrahydropyridine-5-substituted indole and preparation method and application thereof, and the structure is shown in the general formula (I): heterocyclic methylamine and methyl acrylate are raw materials, and an intermediate N-heterocyclic methyl-4-piperidone is obtained by three steps of reaction such as Michael addition, Dieckmann condensation and hydrolysis decarboxylation or the like in sequence, and the object (I) is obtained by condensation reaction of the intermediate and 5-substituted indole. The compound (I) can effectively inhibit propagation of cell lines such as human leukemia K562, Jurkat, U937, THP-1; human esophagus cancer ECA-109; human liver cancer SMMC-7721; human ovary cancer HO-8910; human breast cancer MCF-7 and breast cancer MDA-MB-231; the compound inhibits the propagation of cancer cells by promoting cancer cell apoptosis. The compound can be applied to preparation of anticancer medicament.

The invention provides a shRNA sequence for specifically inhibiting GOS2 gene expression and application thereof, belonging to the technical field of ovarian cancer gene silencing treatment. The invention provides an shRNA sequence for specifically inhibiting the expression of the GOS2 gene, and experiments prove that the silent expression of the GOS2 gene has no obvious influence on the proliferation of the ovarian cancer cell line OVCAR8, but obviously inhibits the migration and infiltration behaviors of the ovarian cancer cell line OVCAR8; and thus, the shRNA sequence has good application in preparing gene medicines for inhibiting the migration and infiltration of the ovarian cancer cells.

In ovarian carcinoma, Müllerian Inhibiting Substance (MIS) type II receptor (MISRII) and the MIS/MISRII signaling pathway are potential therapeutic targets. Conversely, the role of the three MIS type I receptors (MISRI; ALK2, ALK3 and ALK6) in this cancer needs to be clarified. Using four ovarian cancer cell lines and ovarian cancer cells isolated from patients' tumor ascites, the inventors found that ALK2 and ALK3 are the two main MISRIs involved in MIS signaling at low and high MIS concentrations, respectively. Moreover, high MIS concentrations were associated with apoptosis and decreased clonogenic survival, whereas low MIS concentrations improved cancer cell viability. Finally, the inventors showed that anti-MIS antibody B10 inhibited MIS pro-survival effect. These last results open the way to an innovative therapeutic approach to suppress MIS proliferative effect, instead of administering high doses of MIS to induce cancer cell apoptosis.